drugset / Trial / NCT05740371

Safety of Argatroban Infusion in Conduction Disturbances

NCT05740371

Phase 4 Completed 50 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

To determine change of QTc interval during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI)

Timeline

Start
2017-04-18
Primary completion
2021-05-06
Completion
2021-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Argatroban Small molecule 20 ug/kg Intravenous